Jochen Herms
Full professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Glioblastomas exhibit low immunogenicity and a highly immunosuppressive tumor microenvironment (TME) mediated by both tumor cells and tumor associated microglia/macrophages (TAMs). However, biomarkers that allow for specific detection, monitoring and therapy response assessment of the TAM phenotype in glioblastoma are still lacking. To address this gap, we characterized the dynamics of TAM clusters in the TME of experimental SB28 glioblastoma using single-cell RNA sequencing, immunofluorescence, and molecular imaging and identified Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) as a dynamic TAM-specific target. Consequently, we investigated a novel 64 Cu-labeled TREM2 radiotracer with a blood-brain barrier transport vehicle for translational mapping of TAMs in the TME of glioblastoma. We found strong and highly myeloid cell-specific PET signals that followed the trajectory of TREM2 gene expression from early- towards late-stage tumors. Transient myeloid cell depletion via CSF1R inhibition showed a reduction of TREM2 PET signals compared to placebo and prolonged survival in SB28 glioblastoma mice, while TREM2 stimulation led to increased TREM2 PET signals. Translation into a pilot cohort of patients with glioblastoma revealed strong TREM2 PET signals predominantly at lesion edges and high heterogeneity across individuals, matching with immunohistochemistry. In summary, TREM2 PET imaging has strong potential as an immune cell-specific biomarker for personalized assessment of the TAM phenotype in the TME of patients with glioblastoma.
Year:
2026
Stem-cell-based in vitro models offer promising potential to elucidate human brain cell functions and interactions under physiological and pathological conditions. However, harnessing this potential is impaired by low reproducibility, maturity, or cell-type diversity of existing models. Especially, prolonged incorporation of mature microglia and studies of neuroinflammation have proven challenging. Here, we developed a 3D cortical brain tissue model (3BTM) containing neurons, astrocytes, and microglia with high reproducibility, maturity, and viability. 3BTMs show morphological, functional, and proteomic maturation of all cell types, leading to high similarity to their in vivo counterparts. Incorporated microglia survive for over 6 months and display mature morphology, functions, and gene expression. Importantly, when engineered to model Alzheimer’s disease pathology, 3BTMs recapitulate key disease hallmarks including amyloid deposition, increased phospho-Tau levels, and neuroinflammation, with microglia shifting their transcriptional landscape to disease-relevant signatures. Together, our model offers unprecedented possibilities for studying physiological and pathological states of human brain tissue and translational applications.
Year:
2026
The molecular events that precede overt neurodegeneration in Parkinson’s disease (PD) remain poorly defined. Incidental Lewy body disease (iLBD)—a prodromal state marked by brainstem-predominant Lewy pathology in the absence of clinical symptoms—offers a unique window into early pathogenesis. Here, we applied a multi-omic spatial profiling approach, integrating transcriptomics, proteomics, and α-synuclein seed amplification assays (SAA), to post-mortem midbrain tissue from neurologically unaffected individuals, iLBD cases, and patients with PD. We identified early and spatially distinct molecular alterations in the substantia nigra pars compacta (SNpc) of iLBD cases, including a marked upregulation of the microglial synaptic pruning factor C1QC. These changes emerged independently of overt Lewy pathology or detectable misfolded α-synuclein, as assessed by SAA or proximity ligation assay (PLA), and were preferentially enriched at GABAergic synapses—highlighting the early vulnerability of inhibitory circuits. Notably, these alterations were absent in Alzheimer’s disease cases with comorbid SNpc Lewy pathology, suggesting that α-synuclein aggregation alone is insufficient to trigger SNpc remodeling. Our findings implicate microglia-mediated synaptic dysfunction as an early, preclinical feature of PD and nominate this mechanism as a potential therapeutic target for halting disease progression before the onset of neurodegeneration. *Svenja-Lotta Rumpf & Felix Strübing contributed equally to this work.
Year:
2025
Mitochondria are the primary energy producing organelles in eukaryotic cells. Their location is tied to the cell compartment’s energy requirement. Whether mitochondria are actively transported and retain their motility in neuronal axons of adult animals remains debated. Here we show not only a higher fraction of motile axonal mitochondria than currently described, but also marked differences in transport dynamics across neuronal subtypes. We further show that aggregated tau in the Locus Coeruleus (LC), an early pathological hallmark of Alzheimer’s disease, impairs mitochondrial transport along axons, an effect absent in cortical inhibitory and excitatory neurons. Collectively, we demonstrate the abundant and diverse motility of neuronal mitochondria in vivo , and reveal a correlate of LC vulnerability to tau proteinopathy in neurodegenerative diseases.
Year:
2025
Amyloid beta (Aβ) plaque deposition in the central nervous system (CNS) is a hallmark of Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA), triggering an innate immune response. However, the role of the adaptive immune system is less clear. We investigated immune microenvironment dynamics in APP23 transgenic (APP23-tg) mice modelling CNS amyloid pathology, using single-cell transcriptomics. A significant increase in T-cell populations, particularly CD8+ T-cells, was observed in late stages, clustering around Aβ plaques, indicating a targeted response. A novel Aβ plaque-associated subset of CD8+ T-cells expressing interferon-stimulated genes (ISGs), was found to drive Type-I interferon responses. This subset also produced CXCL10, which mediated non-ISG T-cell trafficking via the CXCL10-CXCR3 axis. Importantly, we corroborated our observations by identifying similar Type-I interferon responses near plaques in human CNS amyloid pathology. These findings highlight a shift from microglia-driven to T-cell-mediated neuroinflammation as amyloid pathology progresses, with implications for time-resolved therapy development.
Year:
2024
Contralateral TSPO-PET signal elevation is associated with persisting epileptic seizures and worse overall survival. A, Contralateral TSPO-PET shows no quantitative difference between patients presenting with ( n = 20) and without ( n = 20) epileptic seizures at inital diagnosis (top). Significant increase of contralateral TSPO expression in patients experiencing persisting epileptic seizures after treatment of the primary tumor site ( n = 8) compared to patients with discontinued seizures ( n = 12; bottom). B, Heatmap of contralateral TSPO-PET signal in anatomically and functionally predefined brain regions ( n = 15) of all patients experiencing epileptic seizures at initial diagnosis highlights two patients (age: in their 70s) with strongest contralateral TSPO expression. Coronal slices of TSPO-PET of these two patients are illustrated in comparison to group average images of patients with discontinued and persisting epileptic seizures after tumor therapy. White arrows point toward the tumor. C, Patients with persisting epileptic seizures indicate significant signal elevation in several contralateral brain regions with predominance in motor cortex, mesial temporal lobe, and occipital lobe compared to patients with discontinued epileptic seizures. *, P D, Matrix of regional TSPO-PET inter-correlation coefficients in comparison of patients with discontinued and persisting seizures as well as controls. Single boxes indicate interregional Pearson’s R . E, Significant increase of the contralateral TSPO-PET signal in patients with short overall survival (≤10.7 months; median split). F, High contralateral TSPO-PET signal (>0.88 SUVr; median split) at initial diagnosis is associated with worse overall survival in patients with glioblastoma. Multivariate Cox regression was adjusted for age, glucocorticoid medication, subsequent radiotherapy, and TSPO-PET signal of the tumor. **, P G and H, Distinct predictive value of contralateral TSPO-PET signal in different sub-regions on overall survival. *, P
Year:
2024
Contralateral hemispheres of SB28 glioblastoma mice indicate signatures of disease-associated myeloid cells and immunosuppression. A, Volcano plot highlights genes with significant upregulation and downregulation in the contralateral hemisphere of SB28 glioblastoma mice (red and blue, respectively) compared to sham. B, qPCR reveals higher expression of genes related to an inflammatory myeloid cell state in contralateral hemispheres of SB28 glioblastoma mice in contrast to sham. C, Illustration of the 50 pathways with highest elevation in immune cells of the contralateral hemisphere of SB28 glioblastoma mice (informed by IPA). Note that 40 out of the 50 pathways with highest activation were related to cell migration (phagocytes, leukocytes), phagocytosis, and immune cell activation (indicated in blue). D, IPA network analysis based on altered gene expression signatures in contralateral hemispheres of SB28 glioblastoma mice in contrast to sham. Depicted is a network plot showing TSPO-mediated associations with poor prognosis (e.g., CCL2) and immunosuppression (e.g., CHI3L1).
Year:
2024
Back-translation into a glioblastoma mouse model pinpoints myeloid cells as the cellular source of contralateral TSPO-PET signal elevations. A, Glioblastoma mice ( n = 15) show higher TSPO-PET signal in the contralateral hemisphere compared to sham injected animals ( n = 14). B, Coronal slices of group average TSPO-PET images of SB28 glioblastoma mice (top row; n = 15) and sham injected mice (bottom row; n = 14). Analyzed planes are indicated upon a CT template. Arrows point to the PET signal elevation in the contralateral hemisphere of SB28 mice. Tumor hemisphere is blurred. C, Whole brain tumor seed correlation analysis shows dependency of contralateral TSPO-PET signals (white arrows) from tumor TSPO-PET signals in SB28 mice ( n = 15). Tumor TSPO-PET signals were extracted using a spherical volume of interest with 1.5 mm diameter and included as a seed in a voxel-wise statistical parametric mapping regression model. D, CD11b positive myeloid cells of the contralateral hemisphere of glioblastoma mice ( n = 13) show higher single-cell TSPO tracer uptake than myeloid cells of sham injected ( n = 14) or healthy control mice ( n = 8; left). Non-myeloid cells show no difference in TSPO tracer uptake between the three conditions (right). E and F, Immunohistochemistry shows higher myeloid cell abundance and increased TSPO in IBA1 positive myeloid cells in contralateral hemispheres of SB28 glioblastoma mice ( n = 3) compared to sham ( n = 4). G, qPCR was used to exclude infiltration of SB28 glioblastoma cells into the contralateral hemispheres in SB28 glioblastoma mice ( n = 8; left). Tumor tissue was used as a positive control. While tumor cells could only be detected in the tumor tissue, TSPO expression was observed in contralateral hemispheres of SB28 glioblastoma mice and exceeded TSPO expression in sham injected ( n = 4) and healthy control mice ( n = 4, right). (Adapted from an image created with BioRender.com .)
Year:
2024
Contralateral TSPO-PET signal elevation is associated with tumor phenotype and localization. A and B, Correlation of contralateral TSPO-PET signals in patients with glioblastoma ( n = 38) with the TSPO-PET signal of the tumor ( A ) and the tumor volume in TSPO-PET, FET-PET ( B , left), and MRI ( B , right). C, Examples of TSPO-PET images derived from patients with distinct tumor extent and TSPO expression in PET indicate distinct contralateral PET signal elevation. D, Overall correlation between corresponding areas of the tumor and the contralateral hemispheres including all 123 brain sub-regions of each individual patient. E, Correlation of regionally defined tumor seed regions with TSPO-PET signals of the 123 sub-regions in the contralateral hemisphere. Surface projection of tumor seed localization (top rows: seed region, colored in black) and corresponding contralateral coefficients of correlation (bottom rows). IFG, inferior-frontal gyrus; ITG, inferior-temporal gyrus; MesTemp, mesio-temporal; MFG, mid-frontal gyrus; Motor, motor area; MTG, mid-temporal gyrus; OFG, orbitofrontal gyrus; SFG, superior-frontal gyrus; STG, superior-temporal gyrus. F, Correlation of both hemispheres within 15 previously defined anatomically and functionally connected brain regions. Highest coefficients of correlation are colored in red, significant correlations are highlighted by thick boundaries.
Year:
2024
Purpose: Current therapy strategies still provide only limited success in the treatment of glioblastoma, the most frequent primary brain tumor in adults. In addition to the characterization of the tumor microenvironment, global changes in the brain of patients with glioblastoma have been described. However, the impact and molecular signature of neuroinflammation distant of the primary tumor site have not yet been thoroughly elucidated. Experimental Design: We performed translocator protein (TSPO)-PET in patients with newly diagnosed glioblastoma ( n = 41), astrocytoma WHO grade 2 ( n = 7), and healthy controls ( n = 20) and compared TSPO-PET signals of the non-lesion (i.e., contralateral) hemisphere. Back-translation into syngeneic SB28 glioblastoma mice was used to characterize Pet alterations on a cellular level. Ultimately, multiplex gene expression analyses served to profile immune cells in remote brain. Results: Our study revealed elevated TSPO-PET signals in contralateral hemispheres of patients with newly diagnosed glioblastoma compared to healthy controls. Contralateral TSPO was associated with persisting epileptic seizures and shorter overall survival independent of the tumor phenotype. Back-translation into syngeneic glioblastoma mice pinpointed myeloid cells as the predominant source of contralateral TSPO-PET signal increases and identified a complex immune signature characterized by myeloid cell activation and immunosuppression in distant brain regions. Conclusions: Neuroinflammation within the contralateral hemisphere can be detected with TSPO-PET imaging and associates with poor outcome in patients with newly diagnosed glioblastoma. The molecular signature of remote neuroinflammation promotes the evaluation of immunomodulatory strategies in patients with detrimental whole brain inflammation as reflected by high TSPO expression.
Year:
2024
Year:
2024
Year:
2024
Collaborators (17)
Krishna P Bhat
Associate Professor
Mayo Clinic Arizona
Martina Schifferer
Nanoscale Hub group leader
Deutsches Zentrum für Neurodegenerative Erkrankungen
Joerg-Christian Tonn
-
Stefan Lichtenthaler
Technical University of Munich
Matthias Brendel
-
Günter Höglinger
Director
Ludwig-Maximilians-Universität München
Joachim Schultze
Deutsches Zentrum für Neurodegenerative Erkrankungen
Silvia Cappello
Associate Professor
Ludwig-Maximilians-Universität München
Adrien Holzgreve
LMU University Hospital
Nikolaus Plesnila
Principal investigator
LMU University Hospital
Robert Perneczky
Professor
Ludwig-Maximilians-Universität München
Marc D Beyer
Deutsches Zentrum für Neurodegenerative Erkrankungen
Sophia Stoecklein
LMU University Hospital
Michael Platten
Heidelberg University
Dominik Paquet
Professor of Neurobiology
University Hospital, LMU Munich
Piero Parchi
Professore Associato di Neurologia
University of Bologna
Lars Paeger
Principal Investigator, Head of In vivo Electrophysiology Laboratory
Deutsches Zentrum für Neurodegenerative Erkrankungen
Make your next move.
Prepare your application
Review drafts before you send them.